PxAlpha is developing a revolutionary rotating shield brachytherapy device that selectively targets cancerous cells, with minimal side effects. Prostate cancer is the second most frequently diagnosed cancer in males, only behind skin cancer, with over 238,000 new cases every year. Current treatments for prostate cancer are successful in fighting the disease, which can be seen by the 99% five year survival rate; however there are serious side effects that diminish a patient’s quality of life. Brachytherapy is an effective treatment often used to fight prostate cancer, but it comes with a high risk of urethral stricture, as well as varying rates of other side effects such as impotence, incontinence, and rectal toxicity. PxAlpha is the only company that offers shielded brachytherapy. This shield diminishes the occurrence of these unwanted side effects, providing the patient with a better quality of life long-term. Out of all the new cases diagnosed every year 81% of them are localized, meaning they are just located in the prostate, and are ideal patients for brachytherapy. PxAlpha’s product, Gadix, is made up of three parts essential to ensuring a high quality of life post brachytherapy, including components for planning, hardware, and delivery assurance. 

Venture Information
Product Development
Medical Devices
Type of Product: 
Radiation Oncology Device
Funding Round: 
Company Information
Ryan Flynn, Ph.D.